Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes-EV-based Therapeutics Summit

Bernd Giebel's Biography



Bernd Giebel, Group Leader, University Hospital Duisburg-Essen

Bernd Giebel studied biology at the University zu Köln and received his PhD in 1996 at the Institute for Developmental Biology in Köln. He runs a lab at the Institute for Transfusion Medicine at the University Hospital Essen. Since 1999 he works with human hematopoietic stem cells and started in 2009 to explore the therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Together with collaboration partners the group demonstrated the therapeutic potential of prepared MSC-EVs in a human GvHD-patient and in different animal models. It is the current goal to optimize the MSC-EV production and characterization process to efficiently translate MSC-EVs into the clinics.

B Giebel is an active member of the International Society of Extracellular Vesicles (ISEV) and coordinated an ISEV position paper regarding the therapeutic application of EVs. Furthermore, he is the president of the German Society of Extracellular Vesicles (GSEV), which he founded together with other German EV experts on March 2nd 2017. More recently B. Giebel got involved in the International Society of Gene and Cell Therapy (ISCT) now heading an exosome working group together with Sai Kiang Lim intending to promote translation of MSC-EVs into the clinics.

Bernd Giebel Image

Mesenchymal Stem Cell-derived Extracellular Vesicles: A Potential New Tool in Regenerative Medicine

Friday, 1 November 2019 at 14:30

Add to Calendar ▼2019-11-01 14:30:002019-11-01 15:30:00Europe/LondonMesenchymal Stem Cell-derived Extracellular Vesicles: A Potential New Tool in Regenerative MedicineExosomes-EV-based Therapeutics Summit in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Human mesenchymal stem/stromal cells (MSCs) represent a promising tool in regenerative medicine. Up to now, more than 1000 NIH-registered clinical trials investigated their immunomodulatory and pro-regenerative therapeutic potential in various diseases, including graft-versus-host disease (GvHD) and ischemic stroke. Despite controversial reports regarding the efficacy of MSC-treatments, MSCs seem to exert their beneficial effects rather in a paracrine manner than by cell replacement. In this context, extracellular vesicles (EVs), such as exosomes and microvesicles, are discussed to execute the MSCs’ therapeutic effects. Indeed, we observed beneficial therapeutic impacts of MSC-EVs in a patient, who suffered from steroid-refractory acute GvHD. Furthermore, beneficial effects were observed in animal models for several different diseases.

According to controversial reports in the MSC field, especially since a phase III clinical trial failed to show clinical efficacy in MSC treated GvHD patients, we have started to compare immunomodulatory effects of independent MSC-EV preparations. Indeed, in our in vitro assays independent MSC-EV fractions reveal different immunomodulatory capabilities. To unravel the basis for these differences we are currently using several methods to dissect the heterogeneity between and within given MSC-EV samples.


Add to Calendar ▼2019-11-01 00:00:002019-11-01 00:00:00Europe/LondonExosomes-EV-based Therapeutics SummitExosomes-EV-based Therapeutics Summit in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com